SCHEMBL1919601

SCHEMBL1919601

CCOC(=O)C1(CCc2ccccc2)CCNCC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.61
KMT2A Q03164 11/20 0.61
LMNA P02545 4/20 0.61
POLB P06746 3/20 0.61
RAB9A P51151 2/20 0.61
NPC1 O15118 1/20 0.61
OPRM1 P35372 3/20 0.59
KDM4E B2RXH2 1/20 0.58
OPRD1 P41143 2/20 0.57
ALDH1A1 P00352 4/20 0.56
MAPT P10636 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
RECQL P46063 1/20 0.54
PKM P14618 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1476096 0.99 MEN1 (0.60) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL18440208 0.87 MEN1 (0.65) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL6841616 0.87 LMNA (0.53) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL962133 0.86 OPRM1 (0.62) MEN1KMT2ALMNARAB9ANPC1
SCHEMBL28801682 0.83 MEN1 (0.46) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL13278647 0.82 MAPK1 (0.62) MEN1KMT2ALMNAPOLBOPRM1
SCHEMBL6522997 0.82 OPRM1 (0.56) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL28049599 0.81 SLC6A2 (0.44) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL12346133 0.81 MEN1 (0.59) MEN1KMT2ALMNAPOLBRAB9A
SCHEMBL16111685 0.79 OPRM1 (0.56) MEN1KMT2ALMNAOPRM1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326645-B9 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT ACRAF (IT) 2013-04-17 EP disclosed
EP-2326645-B1 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT ACRAF (IT) 2012-11-07 EP disclosed
US-20110160201-A1 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT AZIENDE CHIMI. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A. (IT) 2011-06-30 US disclosed
EP-2326645-A1 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2011-06-01 EP disclosed
WO-2010012611-A1 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2010-02-04 WO disclosed
CN-100389113-C Nitrogen-containing heterocyclic compound and drug containing same EISAI CO LTD (JP) 2008-05-21 CN disclosed
CN-1630650-A Nitrogen-containing heterocyclic compound and drug containing same EISAI CO LTD (JP) 2005-06-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160201-A1 COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT TPH1, TPH2, HTR1A MEN1 1132/4885KMT2A 3571/4885LMNA 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.